spasticity post-stroke
Neurology · 2007–2019
No submission for this condition has carried consumer input, including the 3 made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| abobotulinumtoxinA (Clostridium botulinum type A toxin-haemagglutinin complex) Moderate to severe focal spasticity of the lower limb following stroke or other acute neurological event. | Jul 2019 | Recommended with restriction | none received |
| botulinum toxin type A Moderate to severe spasticity of the lower limb following stroke or other acute neurological events (traumatic brain injury, spinal cord injury). | Mar 2019 | Recommended with restriction | none received |
| incobotulinumtoxin A Moderate to severe spasticity of the upper limb following an acute event (expansion from stroke-only to include traumatic brain injury, spinal cord injury,… | Nov 2019 | Recommended with restriction | none received |
| botulinum toxin type A Treatment of moderate to severe spasticity of the upper limb in adults following a stroke, as second line therapy when standard management has failed or as an… | Jul 2008 | Recommended with restriction | no section in document |
| Botulinum toxin type A purified neurotoxin complex Treatment of moderate to severe spasticity of the lower limb in ambulatory adults following a stroke as second line therapy when standard management has failed… | Jul 2008 | Not recommended | no section in document |
| clostridium botulinum type A toxin-haemagglutinin complex Treatment of moderate to severe spasticity of the upper limb in adults following a stroke, as second line therapy when standard management has failed or as an… | Nov 2007 | Recommended with restriction | no section in document |
| Clostridium botulinum type A toxin-haemagglutinin complex Treatment of moderate to severe spasticity of the upper limb in adults following a stroke, as second line therapy when standard management has failed or as an… | Nov 2007 | Recommended with restriction | no section in document |
What the PBS pays
$83M in government benefit over 2024–25, across 155,302 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| botulinum toxin type A | $72.8M |
| Clostridium botulinum type A toxin – haemagglutinin complex | $4.9M |
| clostridium botulinum type A toxin-haemagglutinin complex | $4.9M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.